FAAH GENE MUTATIONS: RISK FACTORS IN DRUG USE/ADDICTION
FAAH 基因突变:吸毒/成瘾的风险因素
基本信息
- 批准号:6864827
- 负责人:
- 金额:$ 28.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-03-01 至 2006-12-31
- 项目状态:已结题
- 来源:
- 关键词:age differencebarbituratescannabinoid receptordrug abusedrug abuse information systemdrug addictiongender differencegene expressiongene mutationgenetic librarygenetic susceptibilityhallucinogenshuman genetic material taginhalation drug abusemass spectrometrynarcoticsnicotinenucleic acid hybridizationopiate alkaloidoxygenasespolymerase chain reactionracial /ethnic differencerecombinant proteinssedative /hypnoticsingle nucleotide polymorphismwestern blottings
项目摘要
DESCRIPTION (provided by applicant): Drug addiction exacts a heavy toll on the affected individuals, their families and civilized society. This basic research proposal in response to PA #00-115 approaches the problem of drug abuse and addiction by identifying, characterizing and biochemically testing genetic variants in fatty acid amide hydrolase (FAAH), the principal catabolic regulator of endocannabinoid levels and the brain endogenous cannabinoid system (ECS) tone that may contribute to vulnerability in this genetically complex disorder. The brain ECS is a recently discovered but evolutionary ancient retrograde signaling pathway with the capacity to continuously modulate (downregulate) neurotransmitter release in many critical neuronal systems, including the mesolimbic dopamine addiction/reward system. It has long been known that cannabis use may be associated with drug abuse and addiction in some vulnerable individuals and animal studies indicate that cannabinoids play a role in addiction. Because brain endogenous cannabinoids have the same receptor targets and activity as exogenous cannabis, the central hypothesis of this proposal is that functionally abnormal genetic variants of FAAH may contribute to the risk of vulnerability for drug abuse and addiction. The long term objectives and aims of this proposal are to identify and biochemically test significant FAAH mutations in anonymous subjects with specific types of drug abuse and to link these mutations as risk factors for vulnerability to drug abuse or dependence. This proposal focuses on genetic mutations identified in preliminary studies of the human FAAH gene. The plan is to genetically, biochemically and functionally evaluate significant human FAAH mutations and to confirm the risk of specific mutant proteins in a large cohort of anonymous DNA samples from specific drug addictions, stratified for age, gender, race/ethnicity to compare with matched controls. Collectively, these experimental aims seek to validate naturally occurring FAAH genetic variants as predictors of vulnerability to drug abuse and dependence so that individuals at greatest risk may be identified early and treatment strategies tested for this major public health problem.
描述(由申请人提供):吸毒成瘾对受影响的个人,他们的家庭和文明社会造成了沉重的代价。响应PA #00-115的这一基础研究提案通过识别、表征和生化测试脂肪酸酰胺水解酶(FAAH)的遗传变异来解决药物滥用和成瘾问题,FAAH是内源性大麻素水平和大脑内源性大麻素系统(ECS)音调的主要分解代谢调节剂,可能导致这种遗传复杂疾病的脆弱性。 脑ECS是最近发现的,但进化古老的逆行信号通路的能力,不断调节(下调)在许多关键的神经元系统,包括中脑边缘多巴胺成瘾/奖励系统的神经递质释放。人们早就知道,大麻的使用可能与一些脆弱个体的药物滥用和成瘾有关,动物研究表明大麻素在成瘾中起作用。由于大脑内源性大麻素具有与外源性大麻相同的受体靶点和活性,因此该提案的中心假设是FAAH的功能异常遗传变异可能导致药物滥用和成瘾的风险。该提案的长期目标和目的是在具有特定类型药物滥用的匿名受试者中识别和生化测试显著的FAAH突变,并将这些突变作为易受药物滥用或依赖影响的风险因素联系起来。 该提案的重点是在人类FAAH基因的初步研究中发现的基因突变。 该计划是从遗传学、生物化学和功能上评估重要的人类FAAH突变,并确认来自特定药物成瘾的大量匿名DNA样本中特定突变蛋白的风险,并按年龄、性别、种族/民族分层,以与匹配的对照组进行比较。 总的来说,这些实验的目的是寻求验证自然发生的FAAH基因变异作为药物滥用和依赖的脆弱性的预测因子,使个人在最大的风险可能被识别早期和治疗策略测试这一重大的公共卫生问题。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JACK C SIPE其他文献
JACK C SIPE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JACK C SIPE', 18)}}的其他基金
ENDOCANNABINOID BIOMARKERS OF OBESITY USING INTEGRATED GENOMICS AND METABOLOMICS
使用综合基因组学和代谢组学研究肥胖的内源性大麻素生物标志物
- 批准号:
7437241 - 财政年份:2007
- 资助金额:
$ 28.16万 - 项目类别:
ENDOCANNABINOID BIOMARKERS OF OBESITY USING INTEGRATED GENOMICS AND METABOLOMICS
使用综合基因组学和代谢组学研究肥胖的内源性大麻素生物标志物
- 批准号:
7294386 - 财政年份:2007
- 资助金额:
$ 28.16万 - 项目类别:
FAAH GENE MUTATIONS: RISK FACTORS IN DRUG USE/ADDICTION
FAAH 基因突变:吸毒/成瘾的风险因素
- 批准号:
7004568 - 财政年份:2004
- 资助金额:
$ 28.16万 - 项目类别:
2-CdA for chronic progressive multiple sclerosis
2-CdA 治疗慢性进行性多发性硬化症
- 批准号:
7042965 - 财政年份:2004
- 资助金额:
$ 28.16万 - 项目类别:
FAAH GENE MUTATIONS: RISK FACTORS IN DRUG USE/ADDICTION
FAAH 基因突变:吸毒/成瘾的风险因素
- 批准号:
6772115 - 财政年份:2004
- 资助金额:
$ 28.16万 - 项目类别:
2CDA IN RELAPSING/REMITTING MULTIPLE SCLEROSIS
2CDA 在复发/缓解多发性硬化症中的作用
- 批准号:
6307349 - 财政年份:1999
- 资助金额:
$ 28.16万 - 项目类别:
2-CHLORODEOXYADENOSINE (2CDA) FOR CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS
2-氯脱氧腺苷 (2CDA) 治疗慢性进行性多发性硬化症
- 批准号:
6307369 - 财政年份:1999
- 资助金额:
$ 28.16万 - 项目类别:
2-CHLORODEOXYADENOSINE (2CDA) FOR CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS
2-氯脱氧腺苷 (2CDA) 治疗慢性进行性多发性硬化症
- 批准号:
6118077 - 财政年份:1998
- 资助金额:
$ 28.16万 - 项目类别:
2CDA IN RELAPSING/REMITTING MULTIPLE SCLEROSIS
2CDA 在复发/缓解多发性硬化症中的作用
- 批准号:
6118102 - 财政年份:1998
- 资助金额:
$ 28.16万 - 项目类别:
2CDA IN RELAPSING/REMITTING MULTIPLE SCLEROSIS
2CDA 在复发/缓解多发性硬化症中的作用
- 批准号:
6279297 - 财政年份:1997
- 资助金额:
$ 28.16万 - 项目类别:
相似海外基金
O-GlcNac Modulation of GABAergic Transmission
O-GlcNac 对 GABA 能传输的调节
- 批准号:
10754746 - 财政年份:2023
- 资助金额:
$ 28.16万 - 项目类别:
Mining Social Media Big Data for Toxicovigilance: Studying Substance Use via Natural Language Processing and Machine Learning Methods
挖掘社交媒体大数据进行毒物警戒:通过自然语言处理和机器学习方法研究药物使用
- 批准号:
10588855 - 财政年份:2022
- 资助金额:
$ 28.16万 - 项目类别:
Abuse-deterrence and prevention of respiratory depression by an oral opioid analgesic and doxapram combination
口服阿片类镇痛药和多沙普仑组合的滥用威慑和预防呼吸抑制
- 批准号:
10383180 - 财政年份:2022
- 资助金额:
$ 28.16万 - 项目类别:
Abuse-deterrence and prevention of respiratory depression by an oral opioid analgesic and doxapram combination
口服阿片类镇痛药和多沙普仑组合的滥用威慑和预防呼吸抑制
- 批准号:
10685942 - 财政年份:2022
- 资助金额:
$ 28.16万 - 项目类别:
Compact Liquid Chromatography for Routine Screening in Drug Treatment Centers
用于戒毒中心常规筛查的紧凑型液相色谱
- 批准号:
10599765 - 财政年份:2022
- 资助金额:
$ 28.16万 - 项目类别:
Basic and Translational Research on General Anesthetics
全身麻醉的基础与转化研究
- 批准号:
10395548 - 财政年份:2021
- 资助金额:
$ 28.16万 - 项目类别:
EPPIC-Net Pain Research - Application for Clinical Trial and Related Activities (OT2)
EPPIC-Net Pain Research - 临床试验及相关活动申请 (OT2)
- 批准号:
10818656 - 财政年份:2021
- 资助金额:
$ 28.16万 - 项目类别:
EPPIC-Net Pain Research - Application for Clinical Trial and Related Activities (OT2)
EPPIC-Net Pain Research - 临床试验及相关活动申请 (OT2)
- 批准号:
10267804 - 财政年份:2021
- 资助金额:
$ 28.16万 - 项目类别:
Basic and Translational Research on General Anesthetics
全身麻醉的基础与转化研究
- 批准号:
10206422 - 财政年份:2021
- 资助金额:
$ 28.16万 - 项目类别:
Extransynaptic GABAA modulators for benzodiazepine refractory status epilepticus
突触外 GABAA 调节剂治疗苯二氮卓类难治性癫痫持续状态
- 批准号:
10372824 - 财政年份:2021
- 资助金额:
$ 28.16万 - 项目类别: